Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3351 | Response and Attention Training Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This project seeks to improve the effectiveness of a novel dissonance-based obesity prevention program that has reduced future BMI gain and overweight/obesity onset by (a) experimentally testing whether implementing it in single- versus mixed-sex groups, which should increase dissonance-induction that contributes to weight gain prevention effects, and (b) experimentally testing whether adding food response and attention training, which theoretically reduces valuation of and attention for high-calorie foods, increases weight gain prevention effects. This randomized trial would be the first to experimentally manipulate these two factors in an effort to produce superior weight gain prevention effects. A brief effective obesity prevention program that can be easily, inexpensively, and broadly implemented to late adolescents at risk for excess weight gain, as has been the case with another dissonance-based prevention program, could markedly reduce the prevalence of obesity and associated morbidity and mortality.
Description: Change in percentage of body fat (Not collected during COVID-19 shelter-at-home order)
Measure: Body Fat Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 monthsDescription: Change in BMI (Not collected during COVID-19 shelter-at-home order)
Measure: Body Mass Index (BMI) Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 monthsDescription: Change in weight concerns. Scale scores range from 0 to 42 with higher scores being indicative of higher weight concerns.
Measure: Weight Concerns Scale from the Eating Disorder Examination Questionnaire (EDE-Q) Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 monthsDescription: Change in depressive symptoms
Measure: Beck Depression Index (BDI) Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 monthsDescription: Change in eating disorder symptoms
Measure: Eating Disorder Interview (EDDI) Time: Baseline, 2 months, 8 months, 14 months, 26 months, and 38 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports